Please login to the form below

Not currently logged in
Email:
Password:

John Thievon named president of Dey Pharma

Former CEO of MiddleBrook Pharmaceuticals to help lead Mylan's integrated speciality pharmaceutical division

Mylan has named John Thievon as president of its integrated speciality pharmaceutical business Dey Pharma.

Thievon joins from MiddleBrook Pharmaceuticals where he was president and CEO.

He has more than 20 years experience in the healthcare industry and while serving as Middlebrook's CEO he oversaw the US pharma company's expansion from 18 employees to 450 and subsequent takeover by Victory Pharma.

He also worked as executive vice president of commercial operations for Adams Respiratory Therapeutics and spent four years at IMS Health.

Mylan's president Heather Bresch said: “Dey has been, and continues to be, a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."

As president of Dey Pharma, Thievon will drive the company's focus on medicines to treat respiratory diseases, severe allergic reactions and psychiatric disorders.

21st December 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics